Pancreatic cancer carries one of the worst prognoses of any cancer diagnosis: fewer than 12 percent of patients survive the first five years. New long-term data from an early clinical trial now show that a personalized mRNA vaccine could fundamentally change this outlook. Among patients whose immune systems responded to the vaccine, seven of eight were still alive four to six years later. The immune response itself showed no sign of fading.
Why Pancreatic Cancer Is So Hard to Treat
Pancreatic adenocarcinoma is usually diagnosed only at an advanced stage because it produces few early symptoms. Even after successful surgery, the cancer frequently returns. Chemotherapy extends survival but rarely cures. Checkpoint inhibitors, immunotherapy drugs that work well against melanoma or lung cancer, show little effect against pancreatic cancer. The reason: tumor cells remodel the surrounding tissue in a way that blocks immune cells from reaching them.
This is precisely what the new approach targets. The vaccine, known as autogene cevumeran (BNT122), is being developed by BioNTech together with US biotechnology company Genentech. The long-term data were analyzed by researchers at Memorial Sloan Kettering Cancer Center in New York.
How the Personalized Vaccine Works
The underlying principle resembles that of the mRNA vaccines developed against Covid-19, but is custom-built for each patient. After surgical removal of the tumor, scientists analyze the specific genetic mutations that distinguish the cancer from healthy cells. These so-called neoantigens form the basis of a tailored mRNA drug that trains the immune system to recognize and attack precisely those mutations. Manufacturing takes approximately eight weeks after surgery.
The vaccine is administered in combination: first chemotherapy, then the mRNA drug alongside the checkpoint inhibitor atezolizumab. Researchers at Memorial Sloan Kettering found that this combination activated CD8+ T cells, a type of immune killer cell that attacks tumor cells directly. The central finding of the long-term analysis: these T cells were still circulating in patients' blood six years after vaccination in undiminished numbers, with no signs of exhaustion.
What the Numbers Mean and What They Do Not
A 90 percent survival rate sounds striking, but requires careful context. This figure applies only to the subgroup of patients whose immune systems had measurably responded to the vaccine, the so-called responders. The first trial phase involved a small number of participants in total. How large the non-responder proportion was, which biological factors determine who responds and who does not, and whether the results translate to larger groups remain open questions.
The US National Cancer Institute, which is backing similar vaccine approaches in kidney cancer and other tumor types, nonetheless sees the breakthrough in the underlying concept: that the immune system can be kept active against pancreatic cancer for many years had not previously been demonstrated.
A Potential Model for Other Cancers
BioNTech is developing personalized mRNA vaccines not only against pancreatic cancer but also against colorectal cancer, melanoma and kidney cancer. The principle of analyzing a tumor's genetics before treatment and manufacturing an individual drug from the results is regarded as a paradigm shift in oncology. It replaces the established approach of treating tumors with standardized chemicals with an immunization tailored to each patient.
Challenges remain: manufacturing is complex and expensive. Whether the process can be scaled for broad use, and at what cost health systems can afford it, will need to be resolved through clinical and political debate in the years ahead.
When the Next Results Are Expected
A follow-up trial involving approximately 260 patients is currently running at multiple centers worldwide. Initial data are not expected before 2027. Only this larger study will show whether the remarkable survival results from the first phase can be replicated, which patient groups benefit most and whether the combination of mRNA vaccine, chemotherapy and checkpoint inhibitor is the key to the outcome.